ARTICLE | Company News
ThromboGenics, Novartis sales and marketing update
May 6, 2013 7:00 AM UTC
ThromboGenics said Novartis' Alcon Inc. unit launched Jetrea ocriplasmin in Germany to treat vitreomacular traction, including when associated with a macular hole of 400 µm or less in diameter. The European Commission approved the product in March (see BioCentury, March 18). ...